Background: Data from the first ∼200 adult real-world U.S. users of the implantable 90-day fluorescence-based glucose sensor, Eversense CGM System, showed 62.3% time in range (TIR, glucose 70-180mg/dL) and 4.1% time <70mg/dL. This report describes CGM data by age in a large cohort (>1600) of users with Eversense.
Methods: Sensor glucose (SG) data were analyzed for users who reached a 90‐day wear period. Mean SG, variability measures (SD, CV), glucose management indicator (GMI), and CGM metrics for 18-24.9, 25-44.9, 45-64.9, ≥65 years of age subgroups were computed. Transmitter wear time was calculated in users with at least 30 wear days.
Results: We evaluated 1656 users (997 with T1D, 261 with T2D, 408 unreported). Percent time in range (TIR), time below ranges (<70 mg/dL and <54 mg/dL), and time above ranges (>180 mg/dL and >250 mg/dL) improved with age, with 52.6% and 69.0% TIR in the youngest and oldest groups, respectively (Table). Transmitter wear time was 82% overall and improved to 87% in those ≥65 years. Percent users achieving goals for targets also improved with age.
Conclusion: Glycemic outcomes improved with age in a large cohort using the implantable Eversense CGM System. Younger adults had favorable outcomes compared to data from the T1D Exchange. Overall, these data suggest that the implanted Eversense CGM system is a valuable tool for management of diabetes.
K. Tweden: Employee; Self; Senseonics. S. Ghosh-Dastidar: Employee; Self; Senseonics. A.D. Dehennis: Employee; Self; Senseonics. F. Kaufman: Advisory Panel; Self; Virta Health Corp. Employee; Self; Senseonics. Stock/Shareholder; Self; Medtronic.
